目的  探讨CA125在上皮性卵巢癌中的表达及其与预后的相关性。方法  回顾性分析247例确诊为上皮性卵巢癌患者的临床资料，所有患者至少随访5年或随访至死亡。采用化学发光免疫法检测CA125，并划分为q1、q2、q3和q4共4个区间。比较CA125在不同临床病理特征患者中的表达差异，比较4个区间的生存情况。采用Logistic回归分析预后因素。结果  CA125在年龄、病理类型、FIGO分期、组织学分化和术后残留病灶大小不同的病例中的表达均具有统计学意义(P<0.05)。q1、q2、q3和q4区间的中位生存期分别为58、40、19和11个月，5年生存率分别为48.4% (30/62)、32.3% (20/62)、21.0% (13/62)和11.5% (7/61)，差异均具有统计学意义(P<0.05)。Logistic回归分析显示，与q1比较，q2、q3和q4预后死亡的OR(95%CI)分别为1.624 (1.445~1.825)、2.447 (1.785~3.355)和4.121 (2.624~6.472)。结论  CA125表达与上皮性卵巢癌不同临床病理特征具有相关性，术前CA125可作为上皮性卵巢癌预后的独立预测因子。

Objective  To explore the expression of CA125 of epithelial ovarian cancer (EOC) and its correlation with the prognosis. Methods  The clinical data of 247 cases that diagnosed with EOC were retrospectively analyzed. All patients were followed up for at least 5 years or till they were dead. CA125 levels were detected by chemiluminescence immunoassay and divided into four intervals, i.e. q1, q2, q3, and q4. The differences of expressions of CA125 of patients with different clinical features and the survival of patients with CA125 levels within four intervals were compared. The prognosis factors were analyzed by Logistic regression analysis. Results  The differences of expressions of CA125 of patients with different age, pathological type, FIGO staging, histological differentiation, and postoperative residual lesion size were statistically significant (P<0.05). The median survival time of the four intervals (q1,q2,q3, and q4) were 58, 40, 19, and 11 months and 5-year survival rates were 48.4%(30/62), 32.3%(20/62), 21.0%(13/62), and 11.5%(7/61). The differences were statistically significant (P<0.05). Logistic regression analysis showed that compared with q1, OR (95%CI) of prognosis of death of q2, q3, and q4 were 1.624 (1.445-1.825), 2.447 (1.785-3.355) and 4.121 (2.624-6.472), respectively. Conclusion  The expression of CA125 is correlated with different clinical pathological characteristics of patients with epithelial ovarian cancer. Preoperative CA125 level may be an independent predictor of prognosis of epithelial ovarian cancer.